Rensselaer team receives NIAID grant to develop antiviral drug for Covid-19
Pharmaceutical Technology
JUNE 28, 2022
grant from the National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) for developing a Covid-19 oral antiviral drug. They analysed whether various Food and Drug Administration (FDA)-approved drugs acting on the hepatitis C protease could attach and hinder SARS-CoV-2 proteases.
Let's personalize your content